Peptide advertising rules in the UK
Peptide advertising is regulated under at least three regimes simultaneously: the Human Medicines Regulations 2012, the CAP / BCAP advertising codes enforced by the ASA, and consumer-protection regulation. This page sets out how those layers interact for the three most common categories — POM advertising, unlicensed-peptide claims, and influencer promotion.
The three regimes
1. Human Medicines Regulations 2012 — Part 12
Part 12 of HMR 2012 prohibits the advertising of prescription-only medicines to the general public, with narrow exceptions for government-authorised public-health campaigns. This is a strict rule: a clinic cannot lawfully run a Facebook ad that names Wegovy, Mounjaro, Ozempic, or Saxenda as the product being offered. The clinic can advertise the service (weight management consultation with a GMC-registered prescriber); it cannot advertise the POM itself.
2. CAP code (non-broadcast) and BCAP code (broadcast)
The CAP and BCAP codes, enforced by the ASA, cover all UK marketing communications. For peptides, the relevant rules include:
- Medicines, medical devices, health-related products and beauty products (CAP section 12 / BCAP section 11). Claims must be substantiated; medicinal claims for unlicensed products are prohibited.
- Misleading advertising (CAP section 3). Before-and-after imagery, weight-loss numbers, and timeline claims all need accurate substantiation.
- Slimming (CAP section 13). Specific rules on weight-loss claims, target audiences (no under-18s), and required warnings.
- Children (CAP section 5). Peptide products cannot be marketed to children or in ways likely to appeal to them.
3. Consumer Protection from Unfair Trading Regulations 2008
The Consumer Protection from Unfair Trading Regulations (CPRs) make misleading commercial practices a civil and (in some cases) criminal matter. Undisclosed commercial relationships in influencer posts, fake reviews, and exaggerated health claims all fall within scope.
POM advertising — what is and isn’t allowed
| Allowed | Not allowed |
|---|---|
| “Weight management consultation with a GMC-registered prescriber.” | “Get Wegovy prescribed online for £159/month.” |
| “Specialist obesity service — NHS and private.” | “Mounjaro now in stock — buy now.” |
| Generic educational content on what GLP-1 therapy involves. | “Same-day Ozempic delivery, no consultation needed.” |
Educational content about a POM (what it is, how it works, who is eligible) is not the same as advertising the POM. The line is whether the communication is designed to promote the use, prescription, or supply of that specific named product.
Unlicensed peptide advertising
The hardest category. Sellers and clinics offering unlicensed peptides (BPC-157, TB-500, MOTS-c, CJC-1295, etc.) typically try to thread the needle between “research only” framing and consumer-facing claims. The ASA has consistently held that thepresentation of an advert is what matters, not the disclaimer at the bottom.
Adverts that combine unlicensed-substance branding with statements like “heals tendon injuries”, “regenerates gut lining”, or “reverses ageing” engage the medicinal-product definition under HMR 2012 regulation 2 and are subject to MHRA action in addition to ASA jurisdiction.
Influencer and affiliate advertising
- All paid or otherwise incentivised content must be clearly disclosed under both the CAP code and the CPRs.
#ad,#sponsored, or a clear “Paid partnership” label at the top of the post. - Disclosure does not cure substantive code breaches. A post that implies a POM is appropriate without a clinical assessment is a breach regardless of disclosure.
- Affiliate links to peptide sellers are commercial advertising. Bloggers, podcasters, and forums that link to affiliate offers with health claims attract the same rules as a paid Facebook ad.
Reporting routes
- ASA — for CAP / BCAP code breaches. How to complain to the ASA.
- MHRA — for unlicensed-medicines issues and POM advertising breaches. Report a problem.
- CQC (or devolved equivalent) if a regulated healthcare provider is the source of the claim.
- Action Fraud for clearly fraudulent product offers (counterfeit pens, take-the-money-and-disappear sellers).
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Get Wegovy delivered to your door — no consultation required”
POM-direct-to-public advertising and a circumvention of clinical assessment. Two breaches in one line.
“Lose 20kg in 12 weeks — guaranteed”
Specific weight-loss numbers attached to a guarantee, with no individual variation acknowledged, breach the CAP slimming rules.
“Buy BPC-157 — heals injuries faster than physio”
Comparative medicinal claim for an unlicensed substance. Engages both ASA and MHRA jurisdiction.
“Sponsored content — but isn't disclosed as paid”
Undisclosed commercial relationship — CAP code breach and a CPR offence.
“Used by professional athletes (with photo)”
Athlete imagery for unlicensed substances has been a recurring ASA target; also creates anti-doping issues.
Sources & further reading
- ASA / CAP advertising codes — asa.org.uk
- ASA — make a complaint — asa.org.uk
- Human Medicines Regulations 2012 — Part 12 (advertising) — legislation.gov.uk
- Report a problem with a medicine or medical device — gov.uk
- Consumer Protection from Unfair Trading Regulations 2008 — legislation.gov.uk
Frequently asked questions
- Can semaglutide or Wegovy be advertised to the UK public?
- No. Direct-to-consumer advertising of prescription-only medicines is prohibited under Part 12 of the Human Medicines Regulations 2012. A clinic can advertise its weight-management service, but it cannot promote the named POM (Wegovy, Mounjaro, Ozempic, Saxenda) to the public.
- What about unlicensed peptides — can sellers advertise them?
- Advertising an unlicensed substance with claims that it treats or prevents disease in humans engages both the medicinal-product definition (regulation 2 HMR 2012) and the CAP / BCAP advertising codes. The ASA has upheld complaints in this area; the MHRA can also take action.
- Do influencer posts count as advertising?
- Yes when there is a paid or commercial relationship. Influencer content promoting peptides falls under both ASA jurisdiction (the CAP code applies to all marketing communications) and the Consumer Protection from Unfair Trading Regulations 2008 on undisclosed commercial relationships.
- Are before-and-after photos allowed?
- They are tightly controlled. Before-and-after imagery for medical, cosmetic, or weight-loss services must accurately represent typical results, not cherry-pick, and not omit material conditions. For unlicensed substances, the photos can amount to implied medicinal claims in themselves.
- Who do I report a peptide advert to?
- ASA for advertising-code breaches, MHRA for unlicensed-medicines issues, and the relevant clinic regulator (CQC / HIS / HIW / RQIA) if a regulated service is making the claim. Action Fraud is appropriate for clearly scam adverts.